Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. is demonstrating promising advancements in its product candidates, with increased projected chances of success for both TN-201 and TN-401, reflecting a growing confidence in their developmental pipeline. The company’s recent data indicates significant improvements in left ventricular mass index (LVMI) and promising outcomes in biomarkers, which could potentially expedite regulatory approval akin to successful peer programs. Furthermore, the positive safety profile of TN-401, coupled with consistent clinical benefits observed in patients, strengthens the overall outlook for the company's future prospects in the treatment of heart disease.

Bears say

Tenaya Therapeutics, Inc. faces significant risks related to potential delays in transitioning its preclinical assets to clinical stages, which could adversely affect market sentiment and result in downward revisions of financial estimates. Additionally, the emergence of safety signals, particularly concerning immune reactions during clinical trials, poses a threat to the company’s ability to maintain investor confidence and achieve its development milestones. Furthermore, inadequate manufacturing capacity may constrain Tenaya's forecasts, compounding the challenges to achieving commercial viability and sustained market presence.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.